We have 3 of 85 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
ABBV-CLS-484 is tolerable, with preliminary evidence of clinical activity in dose escalation, and additional strategies that combine ABBV-CLS-484 with VEGF TKIs, CAR-T therapy, and T cell engagers are being tested in preclinical models.
Brain metastases (BM) from renal cell carcinoma (RCC) significantly affect survival, and disease-specific prognostic tools for patients undergoing stereotactic radiosurgery (SRS) remain limited. We aimed to identify prognostic factors and develop an interpretable machine learning (ML) model for individualized ris...
RCC BM represents a biologically distinct tumor entity shaped by neural adaptation, metabolic reprogramming, and immune dysfunction, and supported clinical trials approval testing lenvatinib plus pembrolizumab and zanzalitinib in RCC BM patients.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
